The FDA’s Oncologic Drugs Advisory Committee on Thursday voted 5-3 against the overall benefit-risk of GSK’s Blenrep as a second-line multiple myeloma treatment in combination with bortezomib and dexamethasone. The committee also voted 7-1 against ...
↧